Catheter with specialized nanosensors could enable earlier detection of bladder cancer, MIT study finds

Andrew Hsieh named Larry and Virginia Gordon Endowed Chair in Prostate and Bladder Cancer Research at Fred Hutch

Andrew Hsieh, who serves as the associate director of Fred Hutch’s Human Biology Division, has been named the inaugural holder of the Larry and Virginia Gordon Endowed Chair in Prostate and Bladder Cancer Research.

September 11, 2026

Vol.52 No.33

Clinical Roundup

Enfortumab vedotin + pembrolizumab improves survival and reduces recurrence risk in muscle-invasive bladder cancer, phase III trial finds

Researchers have found that a combination of enfortumab vedotin and pembrolizumab helps patients with muscle-invasive bladder cancer live longer while reducing the risk that their cancer will return after surgery, according to the results of an international phase III clinical trial.

July 31, 2026

Vol.52 No.30

Drugs & Targets

EMA approves phase III clinical study of Alpha1H bladder cancer therapy

Alpha1H has received regulatory approval from the European Medicines Agency for its phase III clinical study of the therapy in bladder cancer. The approval represents a milestone for the clinical development of Alpha1H and provides a clear regulatory path toward a potential future marketing application in Europe.

July 24, 2026

Vol.52 No.29

Clinical Roundup

Portable ultrasound system could make reliable breast imaging more accessible, MIT study finds

For people at high risk of developing breast cancer, yearly mammograms may not be enough to detect tumors early. To make earlier diagnosis easier, a Massachusetts Institute of Technology team has developed portable detectors based on ultrasound, which could be used much more frequently. The team reports that they have improved the resolution of the images produced by their system, making it easier to spot potential tumors, as well as cysts and microcalcifications.

July 10, 2026

Vol.52 No.27

Drugs & Targets

EC approves Padcev + Keytruda as perioperative treatment option for cisplatin-ineligible patients with resectable muscle-invasive bladder cancer

The European Commission granted Marketing Authorization for Padcev (enfortumab vedotin), in combination with Keytruda (pembrolizumab), as neoadjuvant treatment (before surgery) and then continued after radical cystectomy as adjuvant treatment, for adults with resectable muscle-invasive bladder cancer who are ineligible for cisplatin-containing chemotherapy in the European Union.

June 26, 2026

Vol.52 No.25

Drugs & Targets

FDA approves durvalumab in combination with Bacillus Calmette-Guerin for high-risk non-muscle invasive bladder cancer

FDA approved Imfinzi (durvalumab) in combination with Bacillus Calmette-Guerin for the treatment of adult patients with BCG-naïve, high-risk non-muscle invasive bladder cancer.

June 05, 2026

Vol.52 No.22

Catheter with specialized nanosensors could enable earlier detection of bladder cancer, MIT study finds

YOU MAY BE INTERESTED IN

Andrew Hsieh named Larry and Virginia Gordon Endowed Chair in Prostate and Bladder Cancer Research at Fred Hutch

Enfortumab vedotin + pembrolizumab improves survival and reduces recurrence risk in muscle-invasive bladder cancer, phase III trial finds

EMA approves phase III clinical study of Alpha1H bladder cancer therapy

Portable ultrasound system could make reliable breast imaging more accessible, MIT study finds

EC approves Padcev + Keytruda as perioperative treatment option for cisplatin-ineligible patients with resectable muscle-invasive bladder cancer

FDA approves durvalumab in combination with Bacillus Calmette-Guerin for high-risk non-muscle invasive bladder cancer

Renew today!

Subscriber content

Never miss an issue!

Login